The Delta variant (B.1.617.2) was first found in India and is the dominant strain in the country, the Beta variant (B.1.351) was first discovered in South Africa.
Updated: Jun 3, 2021, 08:40 AM IST
The paediatric trials for the COVID-19 vaccine manufactured by the Bharat Biotech, Covaxin has started at Patna`s All India Institute of Medical Sciences (AIIMS). Covaxin received the Drugs Controller General of India (DCGI) nod to conduct clinical trials in children on May 11.
Dr VK Paul, Member (Health), Niti Aayog had earlier said, Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years.
The Covaxin trials are also slated to take place in 525 subjects at various sites, including AIIMS, Delhi, and Meditrina Institute of Medical Sciences, Nagpur.
HYDERABAD: Indigenously developed Covid-19 vaccine Covaxin is now eyeing the Canadian market with Bharat Biotech and its US partner Ocugen extending their US pact for Covaxin to include Canada as well.
Bharat Biotech and Ocugen on Thursday said they have entered into an amendment to their co-development, supply, and commercialization agreement to expand Ocugen’s exclusive territory to commercialize Covaxin to also include Canada, in addition to its existing rights to commercialise Covaxin in the United States.
As part of this amended deal, just like the US, Ocugen will make an upfront payment and milestone payment upon first commercial sale in Canada to Bharat Biotech. Ocugen will get to retain 45% of the profits from Covaxin sales in Canada while Bharat Biotech will get 55% share of the profits.